61 results about "Tumor immunosuppression" patented technology

The present invention discloses an antibody with double MIC binding activity and application thereof. The antibody comprises at least one heavy chain variable region comprising three CDRs and at least one light chain variable region comprising three CDRs, the light chain variable region and the heavy chain variable region thereof The CDR sequence of the chain variable region is described in SEQ ID NO.1-30. The anti-MIC antibody of the present invention has a good affinity effect on various MICA and MICB proteins, especially has binding activity on soluble MICA*008, MICA*010, MICA*002, MICA*009 and MICB*005, through Adsorption of NKG2D ligands in human blood or plasma, including soluble MICA, MICB molecules and immune complexes composed of MICA / B and anti-MIC monoclonal antibody drugs, can relieve the tumor immunosuppressive effect caused by the abnormal increase of MIC protein.

The present invention relates to the field of tumor cell immunotherapy, and in particular to a recombinant lentivirus and its application. The recombinant lentivirus contains a chimeric antigen receptor, and the chimeric antigen receptor mainly includes a signal peptide, an antigen recognition region, a transgenic A membrane region, an intracellular co-stimulatory signal transduction domain and a CD3ζ signal transduction domain are formed in series; wherein, the intracellular co-stimulatory signal transduction domain mainly includes the intracellular region of human TLR2. The GPC3 CAT T cells prepared by the present invention have a strong cell killing effect on liver cancer cells, and highly express Th1 cytokines, which can greatly stimulate the tumor killing effect caused by non-CAR T cells, and can effectively prevent the escape and potential of GPC3 tumor cells. The threat of recurrence, and T cells expressing this chimeric antigen receptor can kill tumor cells to the greatest extent, with little damage to normal tissues, and can break through the tumor immunosuppressive microenvironment, thus having better curative effect on solid tumors.

The invention relates to a single chimeric converter for a T-cell signal and application thereof, which belongs to the fields of molecular biology and immunology. Specifically speaking, the single chimeric converter is formed by connection of a polypeptide highly efficiently bonding with immunosuppression molecules on the surfaces of tumor cells and / or tumor matrix cells to a transmembrane domain originated from a high-affinity receptor and an intracellular peptide fragment of a costimulatory signal molecule through a hinge structure. Out-membrane polypeptide receives a signal of the immunosuppression molecules on the surfaces of tumor cells and / or tumor matrix cells and transmits the signal into a cell, a second signal of immune cells is activated through the intracellular peptide fragment of the costimulatory signal molecule, so multiplication capacity of the immune cells and the secretion function of cell factors are enhanced, and the survival time of the activated immune cells is prolonged; thus, side-effects of a tumor immunosuppression microenvironment on adoptive cell therapy effector cells are overcome.